OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma - de Velasco, Guillermo; Eigentler, Thomas; Isambert, Nicolas; Mouton, Julie; Robert, Caroline; Schusterbauer, Claudia Michaela; Vijayakumar, Jayanthi (Journal of clinical oncology, 2023)